Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Solutions Licenses Low-Density Microarray Technology from Affymetrix

NEW YORK, Jan 4 – Affymetrix has granted Genomic Solutions a non-exclusive license to commercialize low and medium density microarrays, the companies announced Thursday.

Under the agreement, Genomic Solutions will provide Affymetrix with fees and royalty payments on arrays it sells. Genomic Solutions plans to build upon its line of GeneMap microarrays to include human, mouse and rat array sets as well as arrays specific to diseases and biochemical pathways, a company statement said. Currently, Genomic Solutions only offers a cancer-based microarray.

" Genomic Solutions is pleased to be able to provide this license to our GeneMap array product customers,"  Shannon Richey, vice president of the genomic business unit at Genomic Solutions, said in a statement. " With this license agreement, Genomic Solutions is now well-positioned to provide a broader offering of cDNA and oligonucleotide arrays to the marketplace.

Over 25 companies have licensed array technology from Affymetrix, which holds a sizeable portion of the intellectual property in the field.   

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.